[1]汤丹丹,张 勋,符益纲,等.磁共振波谱在原发性帕金森病治疗效果评估中的应用价值[J].新乡医学院学报,2021,38(8):734-737.[doi:10.7683/xxyxyxb.2021.08.007]
 TANG Dandan,ZHANG Xun,FU Yigang,et al.Value of magnetic resonance spectroscopy in evaluating the therapeutic effect of primary Parkinson′s disease[J].Journal of Xinxiang Medical University,2021,38(8):734-737.[doi:10.7683/xxyxyxb.2021.08.007]
点击复制

磁共振波谱在原发性帕金森病治疗效果评估中的应用价值
分享到:

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
38
期数:
2021年8
页码:
734-737
栏目:
临床研究
出版日期:
2021-08-05

文章信息/Info

Title:
Value of magnetic resonance spectroscopy in evaluating the therapeutic effect of primary Parkinson′s disease
作者:
汤丹丹1张 勋1符益纲2陈松洁1孙鼎明1周 笑2朱明明2常永和3何国军1
(1.徐州医科大学盐城临床学院神经内科,江苏 盐城 224000;2.盐城市第一人民医院磁共振室,江苏 盐城  224000;3.江苏省军区盐城离休干部休养所门诊部,江苏 盐城 224000)
Author(s):
TANG Dandan1ZHANG Xun1FU Yigang2CHEN Songjie1SUN Dingming1ZHOU Xiao2ZHU Mingming2CHANG Yonghe3HE Guojun1
(1.Department of Neurology,Affiliated Yancheng Clinical College of Xuzhou Medical University,Yancheng 224000,Jiangsu Province,China2.Department of Magnetic Resonance,the First People′s Hospital of Yancheng,Yancheng 224000,Jiangsu Province,China3.Department of Outpatient,Yancheng Retirement Center for Retired Cadres,Jiangsu Military Region,Yancheng 224000,Jiangsu Province,China)
关键词:
帕金森病氢质子磁共振波谱帕金森病统一评分量表
Keywords:
Parkinson′s diseaseproton magnetic resonance spectroscopyunified parkinson′s disease rating scale
分类号:
R742.5
DOI:
10.7683/xxyxyxb.2021.08.007
文献标志码:
A
摘要:
目的 探讨磁共振波谱(MRS)在原发性帕金森病(PD)药物治疗效果评估中的作用。方法 选择2019年10月至2020年10月盐城市第一人民医院收治的双侧症状的原发性PD患者20例为研究对象。患者均给予口服多巴丝肼片治疗4周(0.125 g,每日3次)。分别于治疗前后进行氢质子磁共振波谱(1H-MRS)检查并采用PD统一评分量表第三部分(UPDRS-Ⅲ)评分来评估患者运动症状。比较患者治疗前后豆状核、苍白球、丘脑、黑质中N-乙酰天门冬氨酸(NAA)/胆碱(Cho)、NAA/肌酐(Cr)、Cho/Cr比值的变化及UPDRS-Ⅲ评分变化,使用单因素线性回归和多因素线性回归分析患者UPDRS-Ⅲ评分与1H-MRS的相关性。结果 治疗后患者左右两侧豆状核、苍白球、丘脑及黑质中的NAA/Cho、NAA/Cr比值均显著高于治疗前(P<0.05),Cho/Cr比值与治疗前比较差异无统计学意义(P>0.05)。患者治疗后UPDRS-Ⅲ评分显著低于治疗前(P<0.05)。患者治疗前后的NAA/Cho、NAA/Cr比值变化值与UPDRS-Ⅲ评分变化值均呈显著负相关(P<0.05);在校正了年龄、性别和病程等因素后,治疗前后的NAA/Cho、NAA/Cr比值变化值与UPDRS-Ⅲ评分变化值仍呈显著负相关(P<0.05);Cho/Cr比值变化值与UPDRS-Ⅲ评分变化值无相关性(P>0.05)。结论 1H-MRS可用于PD的病情评估及药物疗效评价。
Abstract:
Objective To explore the role of magnetic resonance spectroscopy (MRS) in the evaluation of drug efficacy in primary Parkinson′s disease(PD).Methods Twenty patients with primary PD with bilateral symptoms admitted to Yancheng First People′s Hospital from October 2019 to October 2020 were selected as study objects.All patients were treated with dopashydrazine tablets for 4 weeks(0.125 g,3 times a day).Proton magnetic resonance spectroscopy (1H-MRS) examination was performed,and the motor symptoms of patients were evaluated by the unified PD rating scale Part Ⅲ (UPDRS-Ⅲ) before and after treatment.The changes of the N-acetylaspartate (NAA)/ choline(Cho),NAA/ creatine(Cr) and Cho/Cr ratios in the lenticular nucleus,globus pallidus,thalamus and substantia nigra and the UPDRS-Ⅲ scores were compared before and after treatment.The univariate and multivariate linear regression was used to analyze the correlation between the UPDRS-Ⅲ scores and 1H-MRS.Results The NAA/Cho and NAA/Cr ratios of the left and right sides of the lenticular nucleus,globus pallidus,thalamus and substantia nigra of patients with PD after treatment were significantly higher than those before treatment (P<0.05)there was no significant difference in Cho/Cr ratio before and after treatment (P>0.05).The UPDRS-Ⅲ score of PD patients after treatment was significantly lower than that before tretment (P<0.05).The changes of NAA/Cho and NAA/Cr ratio before and after treatment were negatively correlated with the changes of UPDRS-Ⅲ scores (P<0.05)after adjusting for age,sex and course of disease,the changes of NAA/Cho and NAA/Cr ratio before and after treatment were still negatively correlated with the changes of UPDRS-Ⅲ scores (P<0.05).There was no correlation between the change of Cho/Cr ratio and the change of UPDRS-Ⅲ score (P>0.05).Conclusion 1H-MRS can be used for evaluation of severity and drug efficacy of PD.

参考文献/References:

[1] KARTHIVASHAN G,GANESAN P,PARK S Y,et al.Lipid-based nanodelivery approaches for dopamine-replacement therapies in Parkinson′s disease:from preclinical to translational studies[J].Biomaterials,2020,232:119704.
[2] 崔亚欢,陈乃耀.帕金森病的发病机制研究[J].中华老年心脑血管病杂志,2019,21(1):106-110.
[3] WANG X X,FENG Y,LI X,et al.Prodromal markers of Parkinson′s disease in patients with essential tremor[J].Front Neurol,2020,11:874.
[4] SCHRAG A.Testing the MDS clinical diagnostic criteria for Parkinson′s disease[J].Mov Disord,2018,33(10):1518-1520.
[5] GU S C,YE Q,YUAN C X.Metabolic pattern analysis of 18F-FDG PET as a marker for Parkinson′s disease:a systematic review and meta-analysis[J].Rev Neurosci,2019,30(7):743-756.
[6] QU M,LIN Q,HUANG L,et al.Dopamine-loaded blood exosomes targeted to brain for better treatment of Parkinson′s disease[J].J Control Release,2018,287:156-166.
[7] SONNTAG K C,SONG B,LEE N,et al.Pluripotent stem cell-based therapy for Parkinson′s disease:current status and future prospects[J].Prog Neurobiol,2018,168:1-20.
[8] ZANIGNI S,TESTA C,CALANDRA-BUONAURA G,et al.The contribution of cerebellar proton magnetic resonance spectroscopy in the differential diagnosis among parkinsonian syndromes[J].Parkinsonism Relat Disord,2015,21(8):929-37.
[9] XU H,ZHANG H,ZHANG J,et al.Evaluation of neuron-glia integrity by in vivo proton magnetic resonance spectroscopy:implications for psychiatric disorders[J].Neurosci Biobehav Rev,2016,71:563-577.
[10] VON JONQUIERES G,SPENCER Z H T,ROWLANDS B D,et al.Uncoupling N-acetylaspartate from brain pathology:implications for canavan disease gene therapy[J].Acta Neuropathol,2018,135(1):95-113.
[11] 中华医学会神经病学分会帕金森病及运动障碍学组,中国医师协会神经内科医师分会帕金森病及运动障碍专业委员会.中国帕金森病的诊断标准(2016版)[J].中华神经科杂志,2016,49(4):268-271.
[12] 中华医学会神经病学分会帕金森病及运动障碍学组.中国帕金森病治疗指南(第三版)[J].中华神经科杂志,2014,47(6):428-433.
[13] GOETZ C G,TILLEY B C,SHAFTMAN S R,et al.Movement Disorder Society-sponsored revision of the Unified Parkinson′s Disease Rating Scale (MDS-UPDRS):scale presentation and clinimetric testing results[J].Mov Disord,2008,23(15):2129-70.
[14] 梁建庆.帕金森病的发病机制、诊断标准及治疗策略[J].解放军医学杂志,2018,43(8):631-635.
[15] PARK G H J,YANG S H,BAEK H M.900MHz 1H-/13C-NMR analysis of 2-hydroxyglutarate and other brain metabolites in human brain tumor tissue extracts [J].PLoS One,2018,13(9):e0203379.
[16] WESLEY U V,BHUTE V J,HATCHER J F,et al.Local and systemic metabolic alterations in brain,plasma,and liver of rats in response to aging and ischemic stroke,as detected by nuclear magnetic resonance (NMR) spectroscopy [J].Neurochem Int,2019,127:113-124.
[17] ORBAN A,GARG G,SAMMI M K,et al.Effect of high-intensity exercise on multiple sclerosis function and phosphorous magnetic resonance spectroscopy outcomes[J].Med Sci Sports Exerc,2019,51(7):1380-1386.
[18] SAILASUTA N,ANANWORANICH J,LERDLUM S,et al.Neuronal-glia markers by magnetic resonance spectroscopy in HIV before and after combination antiretroviral therapy [J].J Acquir Immune Defic Syndr,2016,71(1):24-30.
[19] BOBAN J,KOZIC D,TURKULOV V,et al.HIV-associated neurodegeneration and neuroimmunity:multivoxel MR spectroscopy study in drug-nave and treated patients[J].Eur Radiol,2017,27 (10):4218-4236.
[20] SARAC H,OZRETIC D,HENIGSBERG N,et al.Proton magnetic resonance spectroscopy in huntington′s disease accompanying neuroborreliosis[J].Psychiatr Danub,2017,29(2):226-230.
[21] SHEN Z,LEI J,LI X,et al.Multifaceted assessment of the APP/PS1 mouse model for Alzheimer′s disease:applying MR-S,DTI,and ASL [J].Brain Res,2018,1698:114-120.
[22] BURMANN B M,GEREZ J A,MATECKO-BURMANN I,et al.Regulation of α-synuclein by chaperones in mammalian cells [J].Nature,2020,577(7788):127-132.
[23] CHAUDHARY S,KUMARAN S S,GOYAL V,et al.Frontal lobe metabolic alterations characterizing Parkinson′s disease cognitive impairment [J].Neurol Sci,2021,42(3):1053-1064.
[24] 庄蓉,张辉,职璞,等.磁共振波谱在强迫障碍中的研究进展[J].国际精神病学杂志,2020,47(2):227-229,246.
[25] WANG W,SUN H,SU X,et al.Increased right amygdala metabolite concentrations in the absence of atrophy in children and adolescents with PTSD [J].Eur Child Adolesc Psychiatry,2019,28(6):807-817.

相似文献/References:

[1]马琪林,鲁丛霞,蔡琰,等.帕金森病患者血小板线粒体谷氨酸载体和复合物活性研究 [J].新乡医学院学报,2007,24(02):114.
[2]洪丽,李珂,闫晓海,等.瞬目反射与肛门括约肌肌电图对帕金森病患者病情分期判定的意义[J].新乡医学院学报,2012,29(12):936.
[3]朱丰霞,常海敏,段 瑛,等.人参皂苷 Rg1对帕金森病小鼠黑质中酪氨酸羟化酶及ephrinB2和磷酸化 c-Jun表达的影响[J].新乡医学院学报,2014,31(10):781.[doi:10.7683/xxyxyxb.2014.10.003]
[4]魏家彬,杨 帆,王淑秀.人参皂苷Rg1对1甲基4苯基1,2,3,6四氢吡啶诱导的帕金森病小鼠黑质酪氨酸蛋白激酶A4表达的影响[J].新乡医学院学报,2015,32(05):404.
[5]李 乐,黄志勇,贺文麟.血浆同型半胱氨酸、催乳素水平与帕金森病及帕金森病痴呆相关性分析[J].新乡医学院学报,2015,32(05):438.
[6]宋金辉,王普清,丁旭东,等.节律性视觉刺激对帕金森病患者运动功能及平衡能力的影响[J].新乡医学院学报,2014,31(12):1006.[doi:10.7683/xxyxyxb.2014.12.011]
[7]孙 冰,徐玉英.氧化苦参碱对帕金森小鼠中枢神经系统氧化应激的影响[J].新乡医学院学报,2020,37(6):509.[doi:10.7683/xxyxyxb.2020.06.002]
 SUN Bing,XU Yuying.Effects of oxymatrine on oxidative stress of central nervous system in Parkinson mice[J].Journal of Xinxiang Medical University,2020,37(8):509.[doi:10.7683/xxyxyxb.2020.06.002]
[8]张静怡,邓永宁,张 萌,等.Sirt3基因过表达慢病毒载体的构建及其在人神经母细胞瘤SH-SY5Y细胞中的表达[J].新乡医学院学报,2021,38(1):006.[doi:10.7683/xxyxyxb.2021.01.002]
 ZHANG Jingyi,DENG Yongning,ZHANG Meng,et al.Construction of lentiviral vector with Sirt3 gene overexpression and its expression in human neuroblastoma SH-SY5Y cells[J].Journal of Xinxiang Medical University,2021,38(8):006.[doi:10.7683/xxyxyxb.2021.01.002]
[9]赵雪薇,陈珮琪,牛延翔,等.帕金森病的病因及发病机制研究进展[J].新乡医学院学报,2021,38(4):378.[doi:10.7683/xxyxyxb.2021.04.018]
[10]谷晓源,车祥源,马 静,等.过氧化物酶体增殖物激活受体γ辅激活剂-1α rs2946385基因多态性与帕金森病的相关性[J].新乡医学院学报,2021,38(9):822.[doi:10.7683/xxyxyxb.2021.09.005]
 GU Xiaoyuan,CHE Xiangyuan,MA Jing,et al.Correlation between peroxisome proliferator-activated receptor γ coactivator 1α rs2946385 gene polymorphism and Parkinson′s disease[J].Journal of Xinxiang Medical University,2021,38(8):822.[doi:10.7683/xxyxyxb.2021.09.005]

更新日期/Last Update: 2021-08-05